APRE - Aprea Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
Total Revenue
0
0
0
Cost of Revenue
-
-
-
Gross Profit
-
-
-
Operating Expenses
Research Development
17,304
14,195
13,393
Selling General and Administrative
5,160
2,295
2,460
Total Operating Expenses
22,464
16,489
15,852
Operating Income or Loss
-22,464
-16,489
-15,852
Interest Expense
14
0
0
Total Other Income/Expenses Net
2,811
961
662
Income Before Tax
-19,667
-15,528
-15,190
Income Tax Expense
-
-
-
Income from Continuing Operations
-19,667
-15,528
-15,190
Net Income
-19,667
-15,528
-15,190
Net Income available to common shareholders
-19,667
-15,528
-15,190
Reported EPS
Basic
-
-1.65
-1.61
Diluted
-
-1.65
-1.61
Weighted average shares outstanding
Basic
-
9,429
9,429
Diluted
-
9,429
9,429
EBITDA
-
-15,520
-15,182